文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

多维数据精准分型扩张型心肌病

Precision Phenotyping of Dilated Cardiomyopathy Using Multidimensional Data.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

本研究基于英国衍生队列(n=426)和荷兰验证队列(n=239)的扩张型心肌病(DCM)患者,利用临床、遗传、心脏磁共振和蛋白质组学数据,通过机器学习识别出三种可重复的DCM亚型,并验证其预后价值。新亚型分型可提升风险预测(C统计量从0.60升至0.76),并发现白细胞介素4受体α(IL-4Rα)为新型预后生物标志物。

要点

  • 识别出三种DCM亚型:促纤维化代谢型、轻度非纤维化型、双心室受损型。
  • 促纤维化代谢型特征为糖尿病更多、普遍心肌纤维化、右室功能保留和肌酐升高。
  • 5个变量(左/右室收缩末期容积、左房容积、心肌纤维化、肌酐)即可分类,提升预后预测。

核心结论

  • 三种可重复、机制不同的DCM亚型被识别,为传统风险模型增加预后价值,可能改善患者选择以实现精准医学。

研究设计与样本

  • 纵向观察性研究,英国衍生队列n=426(中位年龄54岁,67%男性),荷兰验证队列n=239(中位年龄56岁,64%男性),纳入2009-2016年,收集临床、遗传、心脏磁共振和蛋白质组学数据。
  • 采用机器学习Profile回归识别亚型,惩罚多项式逻辑回归验证,嵌套Cox模型比较新分组与传统风险指标。

主要发现

  • 衍生队列和验证队列中,三种亚型预后差异显著(P<0.0001)。
  • 促纤维化代谢型亚型糖尿病更多、普遍心肌纤维化、右室功能保留、肌酐升高。
  • 5个变量(左室和右室收缩末期容积、左房容积、心肌纤维化、肌酐)足以分类。
  • 加入新亚型后C统计量从0.60提升至0.76。
  • IL-4Rα在衍生队列(HR: 3.6; 95%CI: 1.9-6.5; P=0.00002)和验证队列(HR: 1.94; 95%CI: 1.3-2.8; P=0.00005)中均为预后生物标志物。

关键数值与推荐

  • 主要复合终点为心血管死亡、心力衰竭或心律失常事件(中位随访4年)。
  • 亚型分类仅需5个变量:左室和右室收缩末期容积、左房容积、心肌纤维化、肌酐。

临床怎么用

  • 可利用常规临床和影像数据对DCM患者进行亚型分类,改善风险分层。
  • 促纤维化代谢型亚型可能受益于针对纤维化或代谢的干预。
  • IL-4Rα可作为预后评估的候选生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dilated cardiomyopathy (DCM) is a final common manifestation of heterogenous etiologies. Adverse outcomes highlight the need for disease stratification beyond ejection fraction. OBJECTIVES: The purpose of this study was to identify novel, reproducible subphenotypes of DCM using multiparametric data for improved patient stratification. METHODS: Longitudinal, observational UK-derivation (n = 426; median age 54 years; 67% men) and Dutch-validation (n = 239; median age 56 years; 64% men) cohorts of DCM patients (enrolled 2009-2016) with clinical, genetic, cardiovascular magnetic resonance, and proteomic assessments. Machine learning with profile regression identified novel disease subtypes. Penalized multinomial logistic regression was used for validation. Nested Cox models compared novel groupings to conventional risk measures. Primary composite outcome was cardiovascular death, heart failure, or arrhythmia events (median follow-up 4 years). RESULTS: In total, 3 novel DCM subtypes were identified: profibrotic metabolic, mild nonfibrotic, and biventricular impairment. Prognosis differed between subtypes in both the derivation (P < 0.0001) and validation cohorts. The novel profibrotic metabolic subtype had more diabetes, universal myocardial fibrosis, preserved right ventricular function, and elevated creatinine. For clinical application, 5 variables were sufficient for classification (left and right ventricular end-systolic volumes, left atrial volume, myocardial fibrosis, and creatinine). Adding the novel DCM subtype improved the C-statistic from 0.60 to 0.76. Interleukin-4 receptor-alpha was identified as a novel prognostic biomarker in derivation (HR: 3.6; 95% CI: 1.9-6.5; P = 0.00002) and validation cohorts (HR: 1.94; 95% CI: 1.3-2.8; P = 0.00005). CONCLUSIONS: Three reproducible, mechanistically distinct DCM subtypes were identified using widely available clinical and biological data, adding prognostic value to traditional risk models. They may improve patient selection for novel interventions, thereby enabling precision medicine.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Tayal U, Verdonschot JAJ, Hazebroek MR, et al. Precision Phenotyping of Dilated Cardiomyopathy Using Multidimensional Data. J Am Coll Cardiol. 2022. PMID: 35654493. doi:10.1016/j.jacc.2022.03.375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。